Metformin (MET) for the prevention of Alpelisib (ALP)-related Hyperglycemia (HG) in PIK3CA-mutated, Hormone Receptor-Positive (HR[+]) HER2-Negative (HER2[-]) Advanced Breast Cancer (ABC): The METALLICA study

被引：9
|
作者：
Borrego, Manuel Ruiz
Tolosa, Pablo
Blanch, Salvador
Fernandez, Adela
Urriticoechea, Ander
Blancas, Isabel
Saura, Cristina
Rojas, Beatriz
Bermejo, Begona
Ponce, Jose
Gion, Maria
Llabres, Elisenda
Galve, Elena
Cueva, Juan Fernando
Lopez, Ana
Alonso-Romero, Jose L.
Gonzalez-Santiago, Santiago
De Duenas, Eduardo Martinez
Peralta, Fernando Gomez
Ciruelos, Eva
Perez-Garcia, Jose Manuel
Llombart-Cussac, Antonio
Cortes, Javier
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-PD8-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD8-02
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Metformin (MF) in the prevention of hyperglycemia (HG) in patients (pts) with PIK3CA-mutated, hormone receptor (HR) [+]/HER2[-] advanced breast cancer (ABC) treated with alpelisib (ALP) plus fulvestrant (F): METALLICA
    Llombart Cussac, A.
    Perez-Garcia, J. M.
    Blanch, S.
    Tolosa, P.
    Ruiz Borrego, M.
    Gion Cortes, M.
    Fernadez, A.
    Urruticoechea, A.
    Galve, E.
    Cueva Banuelos, J. F.
    Ponce, J.
    Alonso, J. L.
    Capelan, M.
    Martinez, E.
    Bermejo De Las Heras, B.
    Rojas, B.
    Martos, T.
    Lopez, A.
    Gomez-Peralta, F.
    Cortes, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S77 - S77
  • [2] Alpelisib for the treatment of PIK3CA-mutated, hormone receptor-positive, HER2-negative metastatic breast cancer
    Leenhardt, Fanny
    Alexandre, Marie
    Jacot, William
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (06) : 667 - 675
  • [3] Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program
    Roufai, D. Bello
    Goncalves, A.
    Rouge, T. De La Motte
    Akla, S.
    Blonz, C.
    Grenier, J.
    Gligorov, J.
    Saghatchian, M.
    Bailleux, C.
    Simon, H.
    Desmoulins, I
    Tharin, Z.
    Renaud, E.
    Bertho, M.
    Benderra, M-A
    Delaloge, S.
    Robert, L.
    Cottu, P.
    Pierga, J. Y.
    Loirat, D.
    Bertucci, A.
    Renouf, B.
    Bidard, F. C.
    Lerebours, F.
    ONCOGENE, 2023, 42 (23) : 1951 - 1956
  • [4] Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program
    D. Bello Roufai
    A. Gonçalves
    T. De La Motte Rouge
    S. Akla
    C. Blonz
    J. Grenier
    J. Gligorov
    M. Saghatchian
    C. Bailleux
    H. Simon
    I. Desmoulins
    Z. Tharin
    E. Renaud
    M. Bertho
    M-A Benderra
    S. Delaloge
    L. Robert
    P. Cottu
    J. Y. Pierga
    D. Loirat
    A. Bertucci
    B. Renouf
    F. C. Bidard
    F. Lerebours
    Oncogene, 2023, 42 : 1951 - 1956
  • [5] Correction: Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program
    D. Bello Roufai
    A. Gonçalves
    T. De La Motte Rouge
    S. Akla
    C. Blonz
    J. Grenier
    J. Gligorov
    M. Saghatchian
    C. Bailleux
    H. Simon
    I. Desmoulins
    Z. Tharin
    E. Renaud
    M. Bertho
    M-A Benderra
    S. Delaloge
    L. Robert
    P. Cottu
    J. Y. Pierga
    D. Loirat
    A. Bertucci
    B. Renouf
    F. C. Bidard
    F. Lerebours
    Oncogene, 2023, 42 : 1417 - 1417
  • [6] Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
    Andre, Fabrice
    Ciruelos, Eva
    Rubovszky, Gabor
    Campone, Mario
    Loibl, Sibylle
    Rugo, Hope S.
    Iwata, Hiroji
    Conte, Pierfranco
    Mayer, Ingrid A.
    Kaufman, Bella
    Yamashita, Toshinari
    Lu, Yen-Shen
    Inoue, Kenichi
    Takahashi, Masato
    Papai, Zsuzsanna
    Longin, Anne-Sophie
    Mills, David
    Wilke, Celine
    Hirawat, Samit
    Juric, Dejan
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (20): : 1929 - 1940
  • [7] A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer
    Bertho, Marion
    Patsouris, Anne
    Augereau, Paule
    Robert, Marie
    Frenel, Jean-Sebastien
    Blonz, Cyriac
    Campone, Mario
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2021, 17 (02) : 139 - 152
  • [8] Alpelisib: A Well-Tolerated Treatment Option for Patients with HR-Positive, HER2-Negative PIK3CA-Mutated Advanced Breast Cancer
    Diao, Fei-Yu
    GLOBAL MEDICAL GENETICS, 2022, 09 (01): : 1 - 3
  • [9] Risk factor (RF) identification (ID) and hyperglycemia (HG) prevention with alpelisib (ALP) plus fulvestrant (FLV) in PIK3CA-mutated, hormone-receptor positive (HR plus ), human epidermal growth factor-2 negative (HER2-) advanced breast cancer (ABC)
    Burnette, S.
    Poehlein, E.
    Lee, H-J.
    Force, J.
    Westbrook, K.
    Moore, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S470 - S470
  • [10] FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer
    Narayan, Preeti
    Prowell, Tatiana M.
    Gao, Jennifer J.
    Fernandes, Laura L.
    Li, Emily
    Jiang, Xiling
    Qiu, Junshan
    Fan, Jianghong
    Song, Pengfei
    Yu, Jingyu
    Zhang, Xinyuan
    King-Kallimanis, Bellinda L.
    Chen, Wei
    Ricks, Tiffany K.
    Gong, Yutao
    Wang, Xing
    Windsor, Katherine
    Rhieu, Steve Y.
    Geiser, Gerlie
    Banerjee, Anamitro
    Chen, Xiaohong
    Turcu, Francisca Reyes
    Chatterjee, Deb K.
    Pathak, Anand
    Seidman, Jeffrey
    Ghosh, Soma
    Philip, Reena
    Goldberg, Kirsten B.
    Kluetz, Paul G.
    Tang, Shenghui
    Amiri-Kordestani, Laleh
    Theoret, Marc R.
    Pazdur, Richard
    Beaver, Julia A.
    CLINICAL CANCER RESEARCH, 2021, 27 (07) : 1842 - 1849
12345